Home › Funds › Venrock Adviser, LLC › ERAS
Venrock Adviser, LLC position in ERAS
ERASCA INC · Health Care
Venrock Adviser, LLC reported holding 20,089,932 shares of ERAS (ERASCA INC) in its Q3 2026 13F filing — a position valued at US$294.5M, representing 14.31% of its reported portfolio and ranking #2 among its reported holdings. Venrock Adviser, LLC has disclosed ERAS holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's ERAS position evolved
Venrock Adviser, LLC first disclosed a stake in ERAS in Q2 2024 at 16,216,216 shares (US$38.3M). The position peaked in Q2 2026 at 17,891,812 shares, worth US$327.8M. Across 10 filings, Venrock Adviser, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 20,089,932 shares valued at US$294.5M — an increase of 2,198,120 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 16.22M | $38.27M | New |
| Q3 2024 | 16.22M | $44.27M | Hold |
| Q4 2024 | 16.22M | $40.70M | Hold |
| Q1 2025 | 16.22M | $22.22M | Hold |
| Q2 2025 | 17.86M | $22.68M | Add |
| Q3 2025 | 17.86M | $38.93M | Hold |
| Q4 2025 | 17.86M | $66.43M | Hold |
| Q1 2026 | 16.38M | $265.07M | Reduce |
| Q2 2026 | 17.89M | $327.78M | Add |
| Q3 2026 | 20.09M | $294.52M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ERAS and 13F data
ERAS (ERASCA INC) is a Health Care company. 63 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$432.1M), RTW INVESTMENTS, LP (US$329.1M), Siren, L.L.C. (US$193.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ERAS
- Frazier Life Sciences Management, L.P. 29.48M sh · $432.11M · Q3 2026
- RTW INVESTMENTS, LP 22.45M sh · $329.07M · Q3 2026
- Siren, L.L.C. 13.20M sh · $193.48M · Q3 2026
- Paradigm Biocapital Advisors LP 8.00M sh · $117.25M · Q3 2026
- ARCH Venture Management, LLC 7.09M sh · $103.96M · Q3 2026
- Affinity Asset Advisors, LLC 5.59M sh · $81.96M · Q3 2026
- Soleus Capital Management, L.P. 5.11M sh · $74.94M · Q3 2026
- Cormorant Asset Management, LP 5.00M sh · $73.30M · Q3 2026
- Vivo Capital, LLC 4.02M sh · $58.94M · Q3 2026
- EcoR1 Capital, LLC 2.95M sh · $43.25M · Q3 2026
- SAMLYN CAPITAL, LLC 2.54M sh · $37.29M · Q3 2026
- Logos Global Management LP 2.50M sh · $36.65M · Q3 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held ERAS?
Venrock Adviser, LLC has disclosed ERAS holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is Venrock Adviser, LLC's current position in ERAS?
As of Q3 2026, Venrock Adviser, LLC holds 20.09M shares of ERAS (ERASCA INC), valued at $294.52M, representing 14.31% of its reported portfolio and ranking #2.
Has Venrock Adviser, LLC been buying or selling ERAS?
In the latest 13F filing (Q3 2026), Venrock Adviser, LLC increased its position in ERAS. The position peaked in Q2 2026 at 17.89M shares.
Which other funds hold ERAS?
Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Siren, L.L.C., among 63 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.